Compounds > methylhexaneamine
Page last updated: 2024-11-05

methylhexaneamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID7753
CHEBI ID134754
SCHEMBL ID243596
MeSH IDM0573315

Synonyms (47)

Synonym
AC-369
ai3-16556
brn 1731697
nsc 1106
einecs 203-296-1
pentylamine, 1,3-dimethyl-
105-41-9
nsc1106
wln: zy & 1y2
methylhexaneamine
pentylamine,3-dimethyl-
4-methyl-2-hexylamine
2-hexanamine, 4-methyl-
2-amino-4-methylhexane
forthan
1,3-dimethylpentylamine
nsc-1106
1,3-dimethylamylamine
forthane
CHEBI:134754
4-methylhexan-2-amine
geranamine
methylhexanamine
hsdb 8164
4-04-00-00747 (beilstein handbook reference)
4-methyl-2-hexanamine
x49c572yqo ,
dmaa [dietary supplement]
dimethylamylamine
1,3-dmaa
unii-x49c572yqo
AKOS011598451
floradrene
methylhexaneamine [mi]
methylhexaneamine [who-dd]
SCHEMBL243596
W-108787
mfcd00025613
1,3-dimethylamylamine, analytical standard
methylhexanamine hydrochloride, >=98% (hplc)
BCP18792
DTXSID60861715
1,3-dimethyl-pentylamine
Q2594649
D88161
1,3-dimethylamylamine 100 microg/ml in acetonitrile
EN300-92161

Research Excerpts

Effects

ExcerptReferenceRelevance
"Methylhexaneamine (MHA) has been marketed in dietary supplements based on arguments that it is a constituent of geranium (Pelargonium graveolens) leaves, stems, roots or oil, and therefore qualifies as a dietary ingredient. "( Pelargonium oil and methyl hexaneamine (MHA): analytical approaches supporting the absence of MHA in authenticated Pelargonium graveolens plant material and oil.
Avula, B; Bowers, LD; Chittiboyina, AG; Eichner, A; Elsohly, KM; Elsohly, MA; Gul, W; Khan, I; Murphy, TP; Weerasooriya, A, 2012)		1.82

Toxicity

ExcerptReferenceRelevance
" Adverse effects reported in association with preworkout supplements include gastrointestinal symptoms, cardiac arrhythmia, blood pressure increases, and potential effects on lipids and blood glucose."( Efficacy and safety of ingredients found in preworkout supplements.
Ambrose, PJ; Eudy, AE; Gordon, LL; Hockaday, BC; Lee, DA; Lee, V; Luu, D; Martinez, CA, 2013)		0.39
"From February 2012 to February 2014, FDA received 114 reports of adverse events of all kinds involving consumers who ingested OxyELITE Pro."( The Role of Adverse Event Reporting in the FDA Response to a Multistate Outbreak of Liver Disease Associated with a Dietary Supplement.
DeBeck, HJ; Gensheimer, K; Klontz, KC; Lance, SE; LeBlanc, P; Mogen, KM; Monahan, C; Sabo, JL; Salter, M; Seelman, SL; Steigman, DS; Wolpert, BJ, )		0.13
"Vigilant surveillance is required for adverse events linked to the use of dietary supplements."( The Role of Adverse Event Reporting in the FDA Response to a Multistate Outbreak of Liver Disease Associated with a Dietary Supplement.
DeBeck, HJ; Gensheimer, K; Klontz, KC; Lance, SE; LeBlanc, P; Mogen, KM; Monahan, C; Sabo, JL; Salter, M; Seelman, SL; Steigman, DS; Wolpert, BJ, )		0.13
"Military services could readily monitor adverse events associated with dietary supplements using electronic surveys and medical records."( Surveillance of the armed forces as a sentinel system for detecting adverse effects of dietary supplements in the general population.
Austin, KG; Farina, EK; Lieberman, HR, 2018)		0.48

Pharmacokinetics

ExcerptReferenceRelevance
" To our knowledge, no studies have been conducted to determine both the pharmacokinetic profile and physiologic responses of DMAA."( Physiological and pharmacokinetic effects of oral 1,3-dimethylamylamine administration in men.
Bloomer, RJ; Hammond, KG; Presley, CS; Schilling, BK; Yates, CR, 2013)		0.39
"These are the first data to characterize the oral pharmacokinetic profile of DMAA."( Physiological and pharmacokinetic effects of oral 1,3-dimethylamylamine administration in men.
Bloomer, RJ; Hammond, KG; Presley, CS; Schilling, BK; Yates, CR, 2013)		0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
alkylamineAny primary amine in which the substituent attached to nitrogen is an alkyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (35)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (2.86)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's31 (88.57)24.3611
2020's3 (8.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.26 (24.57)
Research Supply Index3.83 (2.92)
Research Growth Index4.35 (4.65)
Search Engine Demand Index53.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (4.65%)5.53%
Reviews4 (9.30%)6.00%
Case Studies9 (20.93%)4.05%
Observational0 (0.00%)0.25%
Other28 (65.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
beta-alanine
[no description available]		3.1810amino acid zwitterion;
beta-amino acid		agonist;
fundamental metabolite;
human metabolite;
inhibitor;
neurotransmitter
creatine
[no description available]		4.1220glycine derivative;
guanidines;
zwitterion		geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent;
nutraceutical
glycine
[no description available]		3.2310alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
glycocyamine
glycocyamine: RN given refers to parent cpd; structure. guanidinoacetate : A monocarboxylic acid anion that is the conjugate base of guanidinoacetic acid, obtained by deprotonation of the carboxy group.. guanidinoacetic acid : The N-amidino derivative of glycine.		3.2310guanidinoacetic acids;
zwitterion		bacterial metabolite;
human metabolite;
mouse metabolite;
nutraceutical;
rat metabolite
nitrates
Nitrates: Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical.		3.2310monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species
caffeine
[no description available]		5.5241purine alkaloid;
trimethylxanthine		adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic
clenbuterol
Clenbuterol: A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma.. clenbuterol : A substituted aniline that is 2,6-dichloroaniline in which the hydrogen at position 4 has been replaced by a 2-(tert-butylamino)-1-hydroxyethyl group.		2.2510amino alcohol;
dichlorobenzene;
ethanolamines;
primary arylamine;
secondary amino compound;
substituted aniline		beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent
amphetamine
Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.. 1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.. amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.		2.610primary amine
octopamine
Octopamine: An alpha-adrenergic sympathomimetic amine, biosynthesized from tyramine in the CNS and platelets and also in invertebrate nervous systems. It is used to treat hypotension and as a cardiotonic. The natural D(-) form is more potent than the L(+) form in producing cardiovascular adrenergic responses. It is also a neurotransmitter in some invertebrates.. octopamine : A member of the class of phenylethanolamines that is phenol which is substituted at the para- position by a 2-amino-1-hydroxyethyl group. A biogenic phenylethanolamine which has been found to act as a neurotransmitter, neurohormone or neuromodulator in invertebrates.		2.3110phenylethanolamines;
tyramines		neurotransmitter
arginine
Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.		3.1810arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical
synephrine
[no description available]		2.2510ethanolamines;
phenethylamine alkaloid;
phenols		alpha-adrenergic agonist;
plant metabolite
1,3-dimethylbutylamine
1,3-dimethylbutylamine: a stimulant; structure in first source		2.6320
melamine
melamine: RN given refers to parent cpd; structure. melamine : A trimer of cyanamide, with a 1,3,5-triazine skeleton.		3.2310triamino-1,3,5-triazinexenobiotic metabolite
n-heptane
Heptanes: Seven-carbon alkanes with the formula C7H16.. heptane : A straight-chain alkane with seven carbon atoms. It has been found in Jeffrey pine (Pinus jeffreyi).		2.6320alkane;
volatile organic compound		non-polar solvent;
plant metabolite
ephedrine
Ephedrine: A phenethylamine found in EPHEDRA SINICA. PSEUDOEPHEDRINE is an isomer. It is an alpha- and beta-adrenergic agonist that may also enhance release of norepinephrine. It has been used for asthma, heart failure, rhinitis, and urinary incontinence, and for its central nervous system stimulatory effects in the treatment of narcolepsy and depression. It has become less extensively used with the advent of more selective agonists.. (-)-ephedrine : A phenethylamine alkaloid that is 2-phenylethanamine substituted by a methyl group at the amino nitrogen and a methyl and a hydroxy group at position 2 and 1 respectively.		2.3110phenethylamine alkaloid;
phenylethanolamines		bacterial metabolite;
environmental contaminant;
nasal decongestant;
plant metabolite;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
nandrolone
Nandrolone: C18 steroid with androgenic and anabolic properties. It is generally prepared from alkyl ethers of ESTRADIOL to resemble TESTOSTERONE but less one carbon at the 19 position.. nandrolone : A 3-oxo Delta(4)-steroid that is estr-4-en-3-one substituted by a beta-hydroxy group at position 17.		2.251017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
anabolic androgenic steroid		human metabolite
octodrine
2-amino-6-methylheptane: 1,3-dimethylamylamine (1,3-DMAA) analog		2.6320alkylamine
deterenol
[no description available]		2.3110
higenamine
higenamine: structure; RN given refers to (+-)-isomer		3.6920norcoclaurine
betadex
beta-Cyclodextrins: Cyclic GLUCANS consisting of seven (7) glucopyranose units linked by 1,4-glycosidic bonds.		2.1110cyclodextrin
cocaine
Cocaine: An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.. cocaine : A tropane alkaloid obtained from leaves of the South American shrub Erythroxylon coca.		2.610benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid		adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
eptifibatide
[no description available]		2.110homodetic cyclic peptide;
macrocycle;
organic disulfide		anticoagulant;
platelet aggregation inhibitor
oxilofrine
oxilofrine: RN given refers to cpd without isomeric designation; structure		2.3110alkylbenzene
phosphorus
Phosphorus: A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions.		3.1810monoatomic phosphorus;
nonmetal atom;
pnictogen		macronutrient
ConditionIndicatedRelationship StrengthStudiesTrials
Tachyarrhythmia
[description not available]		03.0440
Tachycardia
Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia.		08.0440
Dizzyness
[description not available]		02.1710
Hypesthesia
Absent or reduced sensitivity to cutaneous stimulation.		02.1710
Action Tremor
[description not available]		02.1710
Weight Reduction
[description not available]		03.4720
Dizziness
An imprecise term which may refer to a sense of spatial disorientation, motion of the environment, or lightheadedness.		02.1710
Tremor
Cyclical movement of a body part that can represent either a physiologic process or a manifestation of disease. Intention or action tremor, a common manifestation of CEREBELLAR DISEASES, is aggravated by movement. In contrast, resting tremor is maximal when there is no attempt at voluntary movement, and occurs as a relatively frequent manifestation of PARKINSON DISEASE.		02.1710
Weight Loss
Decrease in existing BODY WEIGHT.		03.4720
Emesis
[description not available]		02.4920
Nausea
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.		02.4920
Vomiting
The forcible expulsion of the contents of the STOMACH through the MOUTH.		02.4920
Angor Pectoris
[description not available]		02.110
Coronary Thrombosis
Coagulation of blood in any of the CORONARY VESSELS. The presence of a blood clot (THROMBUS) often leads to MYOCARDIAL INFARCTION.		02.110
Cardiovascular Stroke
[description not available]		02.110
Angina Pectoris
The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is thought to be provoked by a transient stressful situation during which the oxygen requirements of the MYOCARDIUM exceed that supplied by the CORONARY CIRCULATION.		02.110
Myocardial Infarction
NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).		02.110
Out-of-Hospital Cardiac Arrest
Occurrence of heart arrest in an individual when there is no immediate access to medical personnel or equipment.		02.1110
Athletic Injuries
Injuries incurred during participation in competitive or non-competitive sports.		02.1110
Cerebral Concussion
[description not available]		02.1110
Brain Concussion
A nonspecific term used to describe transient alterations or loss of consciousness following closed head injuries. The duration of UNCONSCIOUSNESS generally lasts a few seconds, but may persist for several hours. Concussions may be classified as mild, intermediate, and severe. Prolonged periods of unconsciousness (often defined as greater than 6 hours in duration) may be referred to as post-traumatic coma (COMA, POST-HEAD INJURY). (From Rowland, Merritt's Textbook of Neurology, 9th ed, p418)		02.1110
Drug Overdose
Accidental or deliberate use of a medication or street drug in excess of normal dosage.		03.0410
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		03.0610
Mydriasis
Dilation of pupils to greater than 6 mm combined with failure of the pupils to constrict when stimulated with light. This condition may occur due to injury of the pupillary fibers in the oculomotor nerve, in acute angle-closure glaucoma, and in ADIE SYNDROME.		02.0710
Adverse Drug Event
[description not available]		02.0710
Drug-Related Side Effects and Adverse Reactions
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.		02.0710
Brain Hemorrhage
[description not available]		02.0710
Infarct, Lacunar
[description not available]		02.0710
Dejerine-Roussy Syndrome
[description not available]		02.0710
Intracranial Hemorrhages
Bleeding within the SKULL, including hemorrhages in the brain and the three membranes of MENINGES. The escape of blood often leads to the formation of HEMATOMA in the cranial epidural, subdural, and subarachnoid spaces.		02.0710
Blood Poisoning
[description not available]		02.0710
Death, Sudden
The abrupt cessation of all vital bodily functions, manifested by the permanent loss of total cerebral, respiratory, and cardiovascular functions.		02.0710
Coagulation, Disseminated Intravascular
[description not available]		02.0710
Asystole
[description not available]		02.0710
MODS
[description not available]		02.0710
Disseminated Intravascular Coagulation
A disorder characterized by procoagulant substances entering the general circulation causing a systemic thrombotic process. The activation of the clotting mechanism may arise from any of a number of disorders. A majority of the patients manifest skin lesions, sometimes leading to PURPURA FULMINANS.		02.0710
Heart Arrest
Cessation of heart beat or MYOCARDIAL CONTRACTION. If it is treated within a few minutes, heart arrest can be reversed in most cases to normal cardiac rhythm and effective circulation.		02.0710
Multiple Organ Failure
A progressive condition usually characterized by combined failure of several organs such as the lungs, liver, kidney, along with some clotting mechanisms, usually postinjury or postoperative.		02.0710
Sepsis
Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.		02.0710